Denali Therapeutics Inc

DNLINASDAQ · USD
18.74USD0.00 (-0.80%)
137

Denali Therapeutics Inc (DNLI) Covered Calls

Denali Therapeutics Inc trades in the Biotechnology industry with an IV Rank of 91.27%, high versus the past year. DNLI's highest covered call setup is the $35.00 strike expiring Mar 19, 2027, sorted by theoretical annualized return. It's 85.28% out of the money with 127 days to expiration, a 86.61% return until expiration, and a 248.91% theoretical annualized return. Across the setups shown, annualized returns run from 30.36% to 248.91% at strikes between $20.00 and $35.00, with 127 to 217 days to expiration, as of Nov 12, 2026.

Read more

Running DNLI covered calls helps you generate income from Denali Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best DNLI covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If DNLI stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling DNLI covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given DNLI covered call is worth writing.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus.

2027-03-1912735.0085.280.252.301636.0086.61248.91-1.32+0.25492.05
2027-03-1912722.5019.111.502.60511.0027.0577.75-7.94+0.431,0211.10
2027-06-1721725.0032.350.754.80686.0036.3261.08-3.97+0.4504.05
2027-06-1721722.5019.111.405.40501.0026.5244.61-7.41+0.5284.00
2027-03-1912720.005.881.004.80211.0011.1732.10-5.29+0.552683.80
2027-06-1721720.005.882.306.30341.0018.0530.36-12.18+0.6084.00

As of Nov 12, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank91.27% High
  • Market cap (M$)3,004
  • 52 weeks high-31.36%
  • 52 weeks low22.16%
  • Analyst recommendationStrong Buy
    1.14
  • Target price$35.82
    91.14% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-03
  • P/E—
  • Future P/E—
  • EPS (ttm)-1.74
  • EPS growth next 5 years16.85%

As of Nov 13, 2026